v2.4.1.9
Other-Net, Expense (Income)
 12 Months Ended
Dec. 31, 2014
Nonoperating Income (Expense) [Abstract]  
Other - Net, Expense (Income) [Text Block]
Note 17:    Other–Net, (Income) Expense
Other–net, (income) expense consisted of the following:
 
2014
 
2013
 
2012
Income related to termination of the exenatide collaboration with Amylin (Note 4)
$
—

 
$
(495.4
)
 
$
(787.8
)
Interest expense
148.8

 
160.1

 
177.8

Interest income
(121.0
)
 
(119.7
)
 
(105.0
)
Other (income) expense
(368.3
)
 
(63.9
)
 
41.0

Other–net, (income) expense
$
(340.5
)
 
$
(518.9
)
 
$
(674.0
)

For the year ended December 31, 2014, other–net, (income) expense is primarily related to net gains on investments (Note 7) and income related to the transfer to Boehringer Ingelheim of our license rights to co-promote linagliptin and empagliflozin in certain countries (Note 4). For the years ended December 31, 2013 and 2012, other–net, (income) expense primarily consists of income related to the termination of the exenatide collaboration with Amylin, including income recognized from the transfer to Amylin of exenatide commercial rights in all markets outside the U.S. in 2013 and income recognized from the early payment of the exenatide revenue-sharing obligation by Amylin in 2012 (Note 4).